UCB Awaits Two Regulatory Verdicts For Bimzelx
An EU decision in hidradenitis suppurativa is important, but the long-delayed US decision in psoriasis – and the specifics of the label – is even more so.

An EU decision in hidradenitis suppurativa is important, but the long-delayed US decision in psoriasis – and the specifics of the label – is even more so.